Across TCGA pan-cancer cohorts, C6orf163 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated C6orf163 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher C6orf163 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C6orf163 expression acts as an unfavorable survival marker.

SCLC are the cancer types where C6orf163 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	II,III,IV	0.137	0.700	<.001	48	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: C6orf163 tumor-vs-normal RNA expression · all C6orf163 data types